The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Disease Registry Based Approaches To Determining Molecular Risk Factors For Glaucoma Blindness, And Applying Them In Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$406,355.00
Summary
The Practitioner-Fellow has drawn together very large cohorts of patients from Australia, New Zealand and now internationally who have lost vision from Glaucoma and complications of Diabetes to determine the contributing factors. He has successfully identified major clinical and genetic risk factors for these diseases, and is now applying the knowledge to patients in early stages of disease, so that earlier and more aggressive treatment high risk individuals can lead to improved outcomes.
Molecular Profiling To Identify Therapeutic Targets For Blinding Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Understanding the molecular mechanisms underlying blinding diseases will allow for the development of new therapies. As an ophthalmologist with sub-specialty training in genetic eye diseases, this fellowship will enhance the synergy between my current research and clinical practice. During this fellowship I will lead research to uncover further genetic associations for eye disease, as well as interrogate patient-specific cell lines to elucidate specific signatures of disease development.